Genetic polymorphisms of lncRNA-p53 regulatory network genes are associated with concurrent chemoradiotherapy toxicities and efficacy in nasopharyngeal carcinoma patients. This evidence concerns the gene TP53 and nasopharyngeal carcinoma.